Relationship of tumor PD-L1 expression withEGFRwild-type status and poor prognosis in lung adenocarcinoma

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations

(2016) Mei Ji et al.   CANCER BIOLOGY & THERAPY

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma

(2016) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

(2016) Kyle C. Strickland et al.   Oncotarget

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

(2015) Cheng Lin et al.   Clinical Lung Cancer

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

(2015) Antonio Calles et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

(2015) Wendy A. Cooper et al.   LUNG CANCER

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

(2015) Anyuan Zhong et al.   OncoTargets and Therapy

B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer

(2015) Yixiang Mao et al.   Oncotarget

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

(2015) Yanna Tang et al.   Oncotarget

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

(2014) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

(2014) Yang Zhang et al.   OncoTargets and Therapy

The Current State of Molecularly Targeted Drugs Targeting HGF/Met

(2013) S. Yano et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations

(2010) Miyako Hiramatsu et al.   LUNG CANCER

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

How tumours escape mass destruction

(2008) T J Stewart et al.   ONCOGENE